Katarina Luptakova
Chief Tech/Sci/R&D Officer chez XILIO THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Dr. Katarina Luptakova, MD, is a Chief Medical Officer at Xilio Therapeutics, Inc. Dr. Luptakova was previously employed as a Vice President-Clinical Development by Constellation Pharmaceuticals, Inc. and a Senior Medical Director by Tesaro, Inc. She received her doctorate degree from the University of Commenius.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XILIO THERAPEUTICS INC
-.--% | 01/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Katarina Luptakova
| Sociétés | Poste | Début |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2022 |
Anciens postes connus de Katarina Luptakova
| Sociétés | Poste | Fin |
|---|---|---|
| TESARO INC | Chief Tech/Sci/R&D Officer | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Katarina Luptakova
| University of Commenius | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
